Book a Meeting

Highly Galactosylated Anti-ERBB3 (Duligotuzumab) Antibody (CAT#: BioBet-GA-228ZP) Datasheet

Target
ERBB3
Isotype
IgG1, κ
Description
The Highly Galactosylated Anti-ERBB3 (Duligotuzumab), a biobetter antibody contains with a high level of galactosylation.
Indication
Solid tumors
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced ERBB3 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
ERBB3
Full Name
Erb-B2 Receptor Tyrosine Kinase 3
Background
This gene encodes a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases. This membrane-bound protein has a neuregulin binding domain but not an active kinase domain. It therefore can bind this ligand but not convey the signal into the cell through protein phosphorylation. However, it does form heterodimers with other EGF receptor family members which do have kinase activity. Heterodimerization leads to the activation of pathways which lead to cell proliferation or differentiation. Amplification of this gene and/or overexpression of its protein have been reported in numerous cancers, including prostate, bladder, and breast tumors. Alternate transcriptional splice variants encoding different isoforms have been characterized. One isoform lacks the intermembrane region and is secreted outside the cell. This form acts to modulate the activity of the membrane-bound form. Additional splice variants have also been reported, but they have not been thoroughly characterized. [provided by RefSeq, Jul 2008]
Alternative Names
Patritumab; 1262787-83-6; AMG 888; U3-1287; ERBB3; v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian); LCCS2, lethal congenital contracture syndrome 2; receptor tyrosine-protein kinase erbB-3; HER3; proto-oncogene-like protein c-ErbB-3;
Gene ID
UniProt ID
Cellular Localization
Plasma membrane, Extracellular region or secreted
Genecards
Involvement in Disease
Its related pathways are RET signaling and Signaling by GPCR.
Related Pathways
Tyrosine-protein kinase plays an important role as a cell surface receptor for neurotonin. Binds and is activated by neuregulin-1 (NRG1); ligand binding increases phosphorylation on tyrosine residues and promotes its association with phosphatidylinositol 3-kinase p85 subunit. It may also be activated by CSPG5. Participate in the regulation of myeloid cell differentiation.
Function
Cancer antibody; Controls and Markers antibody; Signaling Transduction antibody
Field of research
Autophosphorylated (PubMed:20351256). Ligand-binding increases phosphorylation on tyrosine residues and promotes its association with the p85 subunit of phosphatidylinositol 3-kinase (PubMed:20682778).
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG1, κ
Antibody Clone
Duligotuzumab
Host
Humanized
Species Reactivity
Human
Description
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant Humanized antibody to Human ERBB3
Indication
Solid tumors

Solid tumors

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany

ISO 9001 Certified - Creative Biolabs Quality Management System.